ES2145425T3 - Comprimidos de valaciclovir que contienen dioxido de silicio coloidal. - Google Patents

Comprimidos de valaciclovir que contienen dioxido de silicio coloidal.

Info

Publication number
ES2145425T3
ES2145425T3 ES96900626T ES96900626T ES2145425T3 ES 2145425 T3 ES2145425 T3 ES 2145425T3 ES 96900626 T ES96900626 T ES 96900626T ES 96900626 T ES96900626 T ES 96900626T ES 2145425 T3 ES2145425 T3 ES 2145425T3
Authority
ES
Spain
Prior art keywords
silicon dioxide
tablets containing
valaciclovir
coloidal
valaciclovir tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96900626T
Other languages
English (en)
Spanish (es)
Inventor
Barry Howard Carter
Lloyd Gary Tillman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2145425(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2145425T3 publication Critical patent/ES2145425T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES96900626T 1995-01-20 1996-01-19 Comprimidos de valaciclovir que contienen dioxido de silicio coloidal. Expired - Lifetime ES2145425T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501127.6A GB9501127D0 (en) 1995-01-20 1995-01-20 Tablet

Publications (1)

Publication Number Publication Date
ES2145425T3 true ES2145425T3 (es) 2000-07-01

Family

ID=10768317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96900626T Expired - Lifetime ES2145425T3 (es) 1995-01-20 1996-01-19 Comprimidos de valaciclovir que contienen dioxido de silicio coloidal.

Country Status (38)

Country Link
US (1) US5879706A (cg-RX-API-DMAC7.html)
EP (1) EP0806943B1 (cg-RX-API-DMAC7.html)
JP (1) JP3350055B2 (cg-RX-API-DMAC7.html)
KR (1) KR100412298B1 (cg-RX-API-DMAC7.html)
CN (2) CN1131026C (cg-RX-API-DMAC7.html)
AP (1) AP666A (cg-RX-API-DMAC7.html)
AT (1) ATE190483T1 (cg-RX-API-DMAC7.html)
AU (1) AU710823B2 (cg-RX-API-DMAC7.html)
BG (1) BG63187B1 (cg-RX-API-DMAC7.html)
BR (1) BR9606769A (cg-RX-API-DMAC7.html)
CA (1) CA2210891C (cg-RX-API-DMAC7.html)
CY (1) CY2182B1 (cg-RX-API-DMAC7.html)
CZ (1) CZ296514B6 (cg-RX-API-DMAC7.html)
DE (1) DE69607146T2 (cg-RX-API-DMAC7.html)
DK (1) DK0806943T3 (cg-RX-API-DMAC7.html)
EA (1) EA000276B1 (cg-RX-API-DMAC7.html)
EE (1) EE03336B1 (cg-RX-API-DMAC7.html)
ES (1) ES2145425T3 (cg-RX-API-DMAC7.html)
FI (1) FI119722B (cg-RX-API-DMAC7.html)
GB (1) GB9501127D0 (cg-RX-API-DMAC7.html)
GE (1) GEP20022752B (cg-RX-API-DMAC7.html)
GR (1) GR3033677T3 (cg-RX-API-DMAC7.html)
HU (1) HU226131B1 (cg-RX-API-DMAC7.html)
IL (1) IL116830A (cg-RX-API-DMAC7.html)
IN (1) IN181318B (cg-RX-API-DMAC7.html)
MY (1) MY126346A (cg-RX-API-DMAC7.html)
NO (1) NO311488B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ298846A (cg-RX-API-DMAC7.html)
OA (1) OA10500A (cg-RX-API-DMAC7.html)
PL (1) PL185307B1 (cg-RX-API-DMAC7.html)
PT (1) PT806943E (cg-RX-API-DMAC7.html)
RO (1) RO118175B1 (cg-RX-API-DMAC7.html)
SK (1) SK282030B6 (cg-RX-API-DMAC7.html)
TR (1) TR199700657T1 (cg-RX-API-DMAC7.html)
UA (1) UA68325C2 (cg-RX-API-DMAC7.html)
UY (2) UY25774A1 (cg-RX-API-DMAC7.html)
WO (1) WO1996022082A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA96448B (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
DK0874631T3 (da) * 1996-01-19 2004-03-22 Glaxo Group Ltd Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
HK1043043B (en) * 1998-12-18 2004-09-10 Abbott Laboratories Controlled release formulation of sodium divalproex
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
EP1383482B1 (en) * 2001-05-01 2007-07-18 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ　グループ　リミテッド 塩酸バラシクロビルの無水結晶形
IL161969A0 (en) * 2001-11-14 2005-11-20 Teva Pharma Synthesis and purification of valacyclovir
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
KR100871621B1 (ko) * 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
AU2004279318C1 (en) 2003-09-12 2020-06-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
DE60301277T2 (de) * 2003-12-09 2006-03-30 Helm Ag Pharmazeutische zubereitung enthaltend valaciclovir
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (ko) 2004-12-06 2012-02-22 에스케이케미칼주식회사 안정성이 개선된 말레인산 암로디핀 약제 조성물
DE602006017188D1 (de) 2005-03-07 2010-11-11 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
EP1891071B1 (en) * 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
WO2007128350A1 (en) * 2006-05-10 2007-11-15 Evonik Degussa Gmbh Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
JP2009538912A (ja) * 2006-05-31 2009-11-12 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素阻害剤の経口制御放出剤形
EP2040684B1 (en) * 2006-07-11 2013-01-23 LEK Pharmaceuticals d.d. Multiple unit tablets
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
KR101665395B1 (ko) * 2009-03-13 2016-10-12 토야마 케미칼 컴퍼니 리미티드 6-플루오로-3-히드록시-2-피라진카르복사미드 함유 정제 및 조립분말
CH703348A1 (de) * 2010-06-29 2011-12-30 Mepha Gmbh Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.
GB2515486A (en) * 2013-06-24 2014-12-31 Kraft Foods R & D Inc Soluble Beverage Ingredients
KR101497508B1 (ko) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (zh) * 2019-07-30 2023-02-10 珠海润都制药股份有限公司 一种盐酸伐昔洛韦片及其制备方法
US20230201234A1 (en) * 2020-06-01 2023-06-29 Shilpa Medicare Ltd Fast dispersible pharmaceutical composition comprising capecitabine
CA3195598A1 (en) * 2020-12-01 2022-06-09 Seok Cheol YOO Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same
WO2024047094A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ATE82680T1 (de) * 1988-05-04 1992-12-15 Smith Kline French Lab Kautablette.
CZ286723B6 (cs) * 1991-01-30 2000-06-14 The Wellcome Foundation Limited Tablety dispergovatelné ve vodě
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet

Also Published As

Publication number Publication date
US5879706A (en) 1999-03-09
WO1996022082A1 (en) 1996-07-25
AP9701057A0 (en) 1997-10-31
PL321361A1 (en) 1997-12-08
PL185307B1 (pl) 2003-04-30
JP3350055B2 (ja) 2002-11-25
NZ298846A (en) 1998-06-26
JPH10512564A (ja) 1998-12-02
GEP20022752B (en) 2002-08-26
HU226131B1 (en) 2008-05-28
RO118175B1 (ro) 2003-03-28
ZA96448B (en) 1996-08-07
DE69607146D1 (de) 2000-04-20
AU710823B2 (en) 1999-09-30
IN181318B (cg-RX-API-DMAC7.html) 1998-05-09
CN1494898A (zh) 2004-05-12
CA2210891A1 (en) 1996-07-25
CN1131026C (zh) 2003-12-17
AP666A (en) 1998-08-24
NO973327L (no) 1997-09-16
AU4453496A (en) 1996-08-07
EA000276B1 (ru) 1999-02-25
GR3033677T3 (en) 2000-10-31
KR100412298B1 (ko) 2004-04-21
UY25778A1 (es) 2000-08-21
BR9606769A (pt) 1997-12-30
BG63187B1 (bg) 2001-06-29
ATE190483T1 (de) 2000-04-15
FI119722B (fi) 2009-02-27
EA199700123A1 (ru) 1997-12-30
SK96497A3 (en) 1998-01-14
CA2210891C (en) 2009-05-19
FI973062L (fi) 1997-09-18
EE03336B1 (et) 2001-02-15
NO973327D0 (no) 1997-07-18
DK0806943T3 (da) 2000-07-24
SK282030B6 (sk) 2001-10-08
EP0806943A1 (en) 1997-11-19
UY25774A1 (es) 2000-10-31
KR19980701524A (ko) 1998-05-15
GB9501127D0 (en) 1995-03-08
UA68325C2 (en) 2004-08-16
EP0806943B1 (en) 2000-03-15
IL116830A (en) 2000-02-29
MY126346A (en) 2006-09-29
CZ229297A3 (cs) 1998-02-18
CY2182B1 (en) 2002-08-23
BG101831A (en) 1998-04-30
PT806943E (pt) 2000-08-31
MX9705459A (es) 1997-10-31
CN1179100A (zh) 1998-04-15
CN1313081C (zh) 2007-05-02
DE69607146T2 (de) 2000-09-21
HK1002851A1 (en) 1998-09-25
NO311488B1 (no) 2001-12-03
CZ296514B6 (cs) 2006-03-15
FI973062A0 (fi) 1997-07-18
OA10500A (en) 2002-04-10
HUP9801872A2 (hu) 1999-10-28
TR199700657T1 (xx) 1998-02-21
HUP9801872A3 (en) 2001-02-28
IL116830A0 (en) 1996-05-14

Similar Documents

Publication Publication Date Title
ES2145425T3 (es) Comprimidos de valaciclovir que contienen dioxido de silicio coloidal.
BR9807742A (pt) EpotilÈneos que são modificados na cadeia lateral
TW200502367A (en) Liquid-crystalline medium
DE69633617D1 (de) Il-17 receptor
DE69111077D1 (de) Chinazolinderivate um die antitumorwirkung zu verbessern.
NO976048D0 (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
TR200200644T2 (tr) Dallandırılmış polikarbonat konteynerleri.
NO962459L (no) Stabilisert vinylkloridsammensetning
ZA961364B (en) 1-Aryl-2-acylamino-ethane compounds
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
ES2192744T3 (es) Mejoras introducidas en o relacionadas con prensas de escoria.
GR3036142T3 (en) Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
ES2173556T3 (es) Nuevos compuestos heterociclicos, su procedimiento de preparacion y los compuestos farmaceuticos que los contienen.
PL352104A1 (en) Oral composition containing perlite
MY100792A (en) Vitamin composition with enhances bioavailability
ATE161713T1 (de) Feuchtigkeitsspender
MA26980A1 (fr) Antagonistes des recepteurs d'histamine.
NO971097L (no) Fyllmiddel
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
NO943336L (no) Chinolinforbindelser
ES2184025T3 (es) Estante.
DE59810106D1 (de) Substituierte 2,4-diamino-1,3,5-triazine
ES2182587T3 (es) Utilizacion de aleaciones de zinc.
UA30250A (uk) Антиоксидантний засіб
HN1997000108A (es) Derivado 6,6,6.6.7- biciclicas sustituido que contiene pirido o pirimido

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 806943

Country of ref document: ES